argenx SE
adimanebart
congenital myasthenic syndromes (CMS)
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for adimanebart in congenital myasthenic syndromes (CMS) are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“CMS registrational study on track to start in third quarter of 2026”